Active broad-market exchange-traded funds at Friday's regular
SPDR S&P 500 (
): +0.63%, with an all-time high
iShares MSCI Emerging Markets Index (
Select Sector SPDR Fund - Financial (
iShares MSCI Japan (
PowerShares QQQ Trust, Series 1 (
): +0.44%, near its 13-year high
Broad Market Indicators
Most broad market exchange-traded funds were lower in pre-market
trading Monday. Actively traded PowerShares QQQ (
) was down 0.9%, after setting a 13-year high of $90.96 on Friday.
Funds focused on Russia were the biggest losers amid concern Moscow
will face punishing sanctions if it intervenes in the crisis in
U.S. stock futures are pointing to a sharply lower open amid
escalating tension in the Ukraine, which sent stocks in Europe
sharply lower and pushed up the price of gold as investors rushed
to safe haven assets. The main S&P 500 Index will be coming off
a new record set on Friday, as data showing consumer sentiment rose
in February and a strong reading on the Chicago PMI outweighed a
negative revision to Q4 economic growth.
Power Play: Commodities
Gold ETFs were among the best performers on Monday, rising along
with the price of the precious metal, as investors moved into safe
haven assets amid rising tensions in Ukraine. Gold gained 1.8% and
silver was up 1.1%. Among rare metal funds, SPDR Gold Trust (GLD)
gained 1.7%; iShares Silver Trust (SLV) was up 1.4%.
Crude was up 2%; United States Oil Fund (USO) gained 2.2%.
Natural gas was up 1.9%; United States Natural Gas Fund (UNG) rose
Winners and Losers
Technology Select Sector SPDR ETF (XLK), iShares Dow Jones US
Technology ETF (IYW), iShares S&P North American Technology ETF
(IGM) and iShares S&P North American Technology-Software Index
(IGV) are flat after closing mixed on Friday. SPDR S&P
International Technology Sector ETF (IPK) was unchanged after
rising to a record Friday.
Among semiconductor ETFs, SPDR S&P Semiconductor (XSD) and
Semiconductor Sector Index Fund (SOXX) were both unchanged
In stocks news, SolarCity (SCTY) was lower nearly 3% in recent
pre-market trade after saying its earnings in 2012 and 2013 will be
restated due to an error made in the overhead expenses in Q112.
The provider of solar energy said the error was found in the
formula for allocating overhead expenses between operating lease
assets and the cost of solar energy system sales.
Select Financial Sector SPDRs (
) was down 2.8% pre-market Monday. Direxion Daily Financial Bull 3X
shares (FAS) was up 2.73%. Its bearish counterpart, FAZ, was up
Among financial stocks, Mack Cali Realty (CLI) reported mixed
financial results for Q4, and said it is lowering its guidance for
funds for operations (FFO) per share in fiscal 2014. The
self-administered and self-managed real estate investment trust
reported Q4 FFO of $0.52 per diluted share, compared with the
prior-year period's $0.66 per share.
Dow Jones U.S. Energy Fund (IYE) dropped 0.9% and Energy Select
Sector SPDR (XLE) was flat.
In corporate news, QR Energy (QRE) reported Q4 revenue that was
short of the Street consensus. QR Energy reported revenue was
$119.3 million for Q4, up from $126.0 million a quarter prior.
Earnings were $0.25 per share, up from a year ago loss of $0.57 per
share. The energy company expects an average of 18,900 to 19,600
barrels per day for Q1 and an average of 19,700 to 20,700 per day
for the full year 2014.
Consumer Staples Select Sector SPDR (XLP), iShares Dow Jones US
Consumer Goods (IYK) and Vanguard Consumer Staples ETF (VDC) were
all unchanged after closing higher on Friday.
In company news, Nu Skin reported Q4 revenue of $1.056 billion,
an 82% improvement over the prior-year period. Revenue was
negatively impacted 4% by foreign currency fluctuations. Earnings
per share for Q4 were $2.02, a 108% year-over-year improvement. The
Street expected Q4 revenue of $1.069 billion and earnings of $1.98
per share, according to Capital IQ estimates.
Health Care SPDR (XLV) fell 0.5%, Vanguard Health Care ETF (VHT)
and iShares Dow Jones US Healthcare (IYH) are flat. All three funds
set new records on Friday. Biotech ETF iShares NASDAQ Biotechnology
Index (IBB) fell 1.6%.
In corporate news, Array BioPharma (ARRY) was up more than 9% in
pre-market trade after reporting positive study results for its
asthma treatment. The company said, ARRY-502, an oral CRTh2
antagonist, was studied in a 184-patient placebo-controlled,
randomized, double-blind Phase 2 trial in mild to moderate
persistent allergic asthma, a population representing more than 12
million patients in the U.S.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.